Anti-obesity agent and food composition for preventing or treating obesity
Basil and coriander extracts provide a safe and effective solution for obesity by reducing weight and fat accumulation through natural components, addressing the limitations of existing treatments.
Patent Information
- Application Number
- JP2023062292
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-04-06
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2038-03-02
AI Technical Summary
Current anti-obesity treatments, including drugs and herbal extracts, have side effects and are not considered safe or effective for long-term use, necessitating the development of a side-effect-free and highly effective anti-obesity agent.
Utilizing basil and coriander extracts or ground products, particularly in powdered or crushed forms, to create an anti-obesity agent that can be incorporated into food compositions, leveraging their natural components to reduce body weight and fat accumulation.
The basil and coriander-based agent effectively reduces body weight, liver weight, and suppresses lipogenic enzymes, while promoting lipolysis and reducing inflammation, offering a safe and effective means to prevent or treat obesity.
Smart Images

Figure 0007589953000001 
Figure 0007589953000002 
Figure 0007589953000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an anti-obesity agent and a food composition for preventing or treating obesity. The anti-obesity agent of the present invention can prevent or treat obesity. [Background technology]
[0002] According to a report by the World Health Organization, at least 1 billion adults are overweight, of which 300 million are obese. Furthermore, these numbers are expected to rise in the absence of medical intervention. Obesity is caused by lifestyle habits such as overeating and lack of exercise, and is caused by an increase in body fat, which leads to metabolic syndrome and lifestyle-related diseases. Obesity is also a cause of metabolic diseases and is associated with coronary heart disease, high blood pressure, type 2 diabetes, cancer, respiratory complications, and osteoarthritis. Currently, the treatment of obesity is generally a combination of dietary therapy and exercise therapy. Meanwhile, research into drug therapy is also being conducted, and anti-obesity drugs such as Reductil (sibutramine hydrochloride) and Xenical have been developed, but side effects have been reported and they have not been approved for manufacture in Japan. In addition, it has been reported that the extract of the medicinal herb Long Peppermint, the extract of Cucurbitaceae plants (Patent Document 1), and the extract of Lithospermum moniliforme (Patent Document 2) have anti-obesity effects, but the effect is not sufficient. Therefore, the development of a safe and effective anti-obesity agent is desired. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] Special Publication No. 2007-513150 [Patent Document 2] Special Publication No. 2009-536223 Summary of the Invention [Problem to be solved by the invention]
[0004] An object of the present invention is to provide a safe anti-obesity agent that can be taken on a daily basis, has no risk of side effects, and is expected to have excellent effects. [Means for solving the problem]
[0005] The present inventors conducted extensive research into safe and highly effective anti-obesity drugs and, as a result, surprisingly found that basil and coriander (cilantro) contain components that have anti-obesity effects. The present invention is based on these findings. Thus, the present invention provides [1] An anti-obesity agent comprising ground basil or coriander or an extract thereof. [2] The anti-obesity agent according to [1], wherein the pulverized material is a pulverized material of leaves, and the extract is an extract of leaves. [3] The anti-obesity agent according to [1] or [2], wherein the extract is an alcohol extract; and [4] A food composition for preventing or treating obesity, comprising the anti-obesity agent according to any one of [1] to [3] and a food or drink. Regarding. Effect of the Invention
[0006] The anti-obesity agent of the present invention can prevent or treat obesity. Moreover, the food composition for preventing or treating obesity of the present invention can prevent or treat obesity by ingesting it. [Brief description of the drawings]
[0007] [Figure 1] 1 is a graph showing the results of administering coriander (cilantro) powder to KKAy mice and measuring the change in liver weight (a) and CPT1α mRNA expression (b). [Diagram 2] 1 is a graph showing the results of administering basil powder to KKAy mice and measuring the change in liver weight (a) and SREPB1c mRNA expression (b). [Diagram 3]1 is a graph showing the results of an investigation into changes in the expression level of CPT1α mRNA in mouse liver cells, Hepa-1 cells, using an ethanol extract of coriander (coriander). [Figure 4] 1 is a graph showing that the expression levels of IL-6 (A) or IL-1β gene (B), which are expressed by mouse preadipocytes (3T3-L1 cells) acting on RAW264.7 cells, are suppressed by coriander (cilantro) or basil. [Diagram 5] 1 is a graph investigating the effects of coriander extract and basil extract on the mRNA expression level of 4-1BB in mouse preadipocytes (3T3-L1 cells). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] [1] Anti-obesity agents The anti-obesity agent of the present invention comprises ground basil or coriander or an extract thereof.
[0009] "basil" The part of basil (Ocimum basilicum) used in the present invention is not particularly limited, and may be the whole plant, roots, stems, leaves, flowers, fruits, or seeds, or a mixture of at least two or more of them, but is preferably the leaves or stems. Basil is a perennial plant of the genus Ocimum in the family Lamiaceae, and its Japanese name is Ocimum basilicum. The variety of basil used in the present invention is not particularly limited, and may be sweet basil, Genovese basil, lemon basil, holy basil, cinnamon basil, Thai basil, mammoth basil, Thai lemon basil, lime basil, licorice basil, or African blue basil. Basil may be used fresh or dried (e.g., freeze-dried) for crushing or extraction. For extraction, it is preferable to process it into a crushed or powdered state in order to improve the extraction efficiency.
[0010] "coriander" The part of coriander (Coriandrum sativum L) used in the present invention is not particularly limited, and may be the whole plant, roots, stems, leaves, flowers, fruits, or seeds, or a mixture of at least two of them, but is preferably the leaves, stems, or roots. When performing a crushing operation or an extraction operation, coriander may be used raw or may be dried (e.g., freeze-dried). When extracting, it is preferable to process it into a crushed or powdered state so as to improve the extraction efficiency. Coriander is also called pakchi in Thai, and the leaves that are eaten raw are sometimes called pakchi.
[0011] Shatter The ground product of basil or coriander in the present invention is not particularly limited as long as it is in a ground state of basil or coriander, but may be, for example, a ground product in the form of powder, granules, or paste, preferably a powder. In addition, powders molded or granulated into, for example, cubes, blocks, or granules may also be preferably used. The process for processing into the ground product is not particularly limited, but may be, for example, a process of grinding the plant body by any method commonly used by those skilled in the art using a grinding device or instrument such as a crusher, mill, blender, mixer, or stone mill. The plant body may be dried before grinding. Examples of the drying process include freeze drying, reduced pressure drying, air drying, and heat drying.
[0012] When the basil or coriander contained in the anti-obesity agent of the present invention is a pulverized product, the average longest diameter of the pulverized product is, but not limited to, 0.01 to 2 mm, preferably 0.01 to 1.5 mm, more preferably 0.01 to 1 mm, even more preferably 0.01 to 0.75 mm, and most preferably 0.01 to 0.5 mm. In addition, 90% or more by weight of the pulverized product can be used that has a longest diameter of 0.01 to 2 mm, preferably 0.01 to 1.5 mm, more preferably 0.01 to 1 mm, even more preferably 0.01 to 0.75 mm, and most preferably 0.01 to 0.5 mm. In addition, 90% or more by weight of the pulverized product can be used that passes through 8.6 mesh (2 mm), 10 mesh (1.7 mm), 16 mesh (1 mm), or 30 mesh (0.5 mm) in the JIS test sieve mesh conversion table. When the maximum diameter of the pulverized product is 2 mm or less, the anti-obesity effect of the present invention is improved, so it is preferable to use one with a maximum diameter of 2 mm or less. The average maximum diameter of the pulverized product can be measured using a known device for measuring particle size. It can also be calculated by arbitrarily selecting 100 pieces from the pulverized product, measuring their maximum diameters using a stereomicroscope, and calculating the average.
[0013] 《Extract》 The extract containing the active ingredient can be extracted by a conventional extraction method used for extracting ingredients derived from plants. The extraction method includes, but is not limited to, solvent extraction, steam distillation, squeezing (direct, high temperature, or low temperature), or supercritical extraction. A combination of these extraction methods, such as squeezing followed by solvent extraction, may also be used, but solvent extraction is preferred. The basil or coriander used for extraction may be used fresh or dried. In addition, it may be processed into a crushed or powdered state before extraction to improve extraction efficiency. (Solvent extraction method) The extraction solvent used in the solvent extraction method is not limited as long as the effective ingredient can be sufficiently extracted in the extraction liquid. For example, an organic solvent, an aqueous solvent, or a mixture of an organic solvent and an aqueous solvent can be used, but an aqueous solvent or a mixture of an organic solvent and an aqueous solvent is preferred, and an aqueous solvent is more preferred.
[0014] Examples of the organic solvent include alcohol, acetone, benzene, ester, ethyl acetate, hexane, chloroform, and diethyl ether, with alcohol being preferred. The alcohol is not limited as long as the active ingredient can be sufficiently extracted into the extract, and examples of the alcohol include monohydric alcohols having 1 to 5 carbon atoms, such as methanol, ethanol, propyl alcohol, isopropyl alcohol, and butyl alcohol, and polyhydric alcohols having 2 to 5 carbon atoms, such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin.
[0015] The aqueous solvent is not limited as long as it contains water, and for example, water, physiological saline, or a buffer solution can be used. Examples of the buffer solution include phosphate buffer, sodium phosphate buffer, sodium carbonate buffer, citrate buffer, citrate phosphate buffer, acetate buffer, and Tris buffer. A preferred aqueous solvent is sodium phosphate buffer. The pH of the aqueous solvent is not particularly limited.
[0016] The extract used in the anti-obesity agent of the present invention can be extracted with a mixture of an organic solvent and an aqueous solvent. The amount of the aqueous solvent contained in the extraction solvent is not limited as long as the active ingredient can be sufficiently extracted into the extract, but the content of the aqueous solvent relative to the total amount of the extraction solvent can be, for example, 50% by weight or more, 70% by weight or more, or 90% by weight or more.
[0017] When the extract is extracted by a solvent extraction method, the extraction temperature is not particularly limited as long as the active ingredient can be sufficiently extracted into the extract, but is preferably -50°C to 100°C, more preferably -25°C to 50°C, even more preferably -25°C to 25°C, even more preferably -10°C to 10°C, and most preferably 0°C to 10°C.
[0018] In addition, it is preferable to carry out the extraction with stirring or shaking so as to improve the extraction efficiency. The extraction time can be appropriately determined depending on the part to be used, such as the root, stem, leaf, flower, fruit, or seed. The extraction time can also be appropriately determined depending on the state of the basil or coriander, that is, whether it is raw or dried, or when it is processed into a crushed or powdered state. Furthermore, the extraction time can be appropriately determined depending on the extraction conditions, such as the temperature of the extract, or the presence or absence of stirring or shaking. The extraction time is usually 1 minute to 72 hours, preferably 1 hour to 48 hours, and most preferably 12 hours to 36 hours.
[0019] (Steam distillation method) The basil or coriander extract contained in the anti-obesity agent of the present invention can be extracted by steam distillation. Steam distillation is a method in which steam is passed through a raw material packed in a column, and the aroma components distilled along with the steam are condensed together with the steam. As the distillation method, any of pressurized steam distillation, normal pressure steam distillation, and reduced pressure steam distillation can be used.
[0020] (Compression method) The pressing method is a method of extracting an extract by applying physical pressure to basil or coriander. There are direct pressing method performed at room temperature, high-temperature pressing method performed at high temperature, and low-temperature pressing method performed at low temperature. The extract contained in the anti-obesity agent of the present invention can be extracted by any pressing method.
[0021] (Supercritical extraction method) The extract contained in the anti-obesity agent of the present invention can be extracted using supercritical extraction. Supercritical extraction is a method of extracting an extract from a specific plant using a substance in a supercritical state. Carbon dioxide can be used as the substance in a supercritical state, for example. Carbon dioxide in a supercritical state has a strong dissolving power, so it is also commonly used for decaffeinating coffee or extracting flavors and pharmaceutical ingredients from natural raw materials such as plants.
[0022] Active ingredients: The active ingredient contained in the anti-obesity agent of the present invention is contained in an extract extracted from basil or coriander. Therefore, basil or coriander contains an active ingredient having an anti-obesity effect, and the crushed product of basil or coriander also contains the active ingredient contained in the extract. As shown in the examples, the crushed product of basil or coriander actually shows an effect as an anti-obesity agent. The active ingredient contained in the basil or coriander extract may be a fraction containing the active ingredient fractionated from the basil or coriander extract, or a purified active ingredient.
[0023] <Anti-obesity effect> BMI (Body Mass Index) is often used as a standard for determining obesity, with the WHO determining that a person is obese if their BMI is 30 or higher, while in Japan, they are determined to be obese if their BMI is 25 or higher. Obesity refers to a state in which there is a health disorder associated with obesity, or a state in which visceral fat has accumulated to such an extent that such a health disorder is predicted, and in the case of obesity, weight loss treatment is required. The antiobesity agent of the present invention is effective in preventing or suppressing obesity, and is also effective in preventing or treating obesity. The anti-obesity effect of the anti-obesity agent of the present invention is not particularly limited, so long as obesity or obesity syndrome is suppressed, and examples of the anti-obesity effect include a reduction in body weight, a reduction in liver weight, an increase in lipolytic enzymes (e.g., CPT1), a decrease in lipolytic enzymes (e.g., SREBP1c), or an increase or induction of differentiation of brown cells.
[0024] The dosage form of the anti-obesity agent of the present invention is not particularly limited, and can include oral and parenteral agents, but oral agents are preferred.The oral agents can include, for example, fine granules, granules, tablets, capsules, and pills, and other solid or powdered preparations, as well as suspensions, emulsions, syrups, and extracts, and other liquid preparations.The parenteral agents can include, for example, injections.
[0025] The anti-obesity agent of the present invention may consist of ground basil or coriander or an extract of basil or coriander, or may contain ground basil or coriander or an extract of basil or coriander. When the anti-obesity agent of the present invention contains ground basil or coriander or an extract of basil or coriander, it may contain other additives.
[0026] When the anti-obesity agent of the present invention is an oral preparation, other additives may include excipients, binders, disintegrants, emulsifiers, lubricants, flow promoters, diluents, preservatives, colorants, fragrances, flavorings, stabilizers, moisturizers, antiseptics, antioxidants, or suspending agents, and specific examples thereof include gelatin, sodium alginate, starch, corn starch, sucrose, lactose, glucose, mannitol, carboxymethylcellulose, dextrin, polyvinylpyrrolidone, crystalline cellulose, soybean lecithin, sucrose, fatty acid esters, talc, magnesium stearate, polyethylene glycol, magnesium silicate, anhydrous silicic acid, and synthetic aluminum silicate.
[0027] When the anti-obesity agent of the present invention is a parenteral agent, other additives may include water-soluble solvents such as physiological saline or Ringer's solution, water-insoluble solvents such as vegetable oil or fatty acid ester, isotonic agents such as glucose or sodium chloride, solubilizing agents, stabilizers, preservatives, suspending agents, or emulsifiers.
[0028] The anti-obesity agent of the present invention may contain 90% by weight or more, 50% by weight or more, 10% by weight or more, or 1% by weight or more of ground basil or coriander or extract.
[0029] The dosage or intake of the anti-obesity agent of the present invention can be appropriately adjusted depending on the formulation, age, sex, degree of obesity or obesity of the subject to be used, etc., but it is preferable that the administration or intake of the anti-obesity agent is an amount that can prevent obesity or obesity, or alleviate or treat obesity or obesity. Specifically, in terms of the amount of basil or coriander extract added, it can be 0.01 to 1000 mg / kg body weight / day, preferably 0.1 to 750 mg / kg body weight / day, more preferably 1 to 500 mg / kg body weight / day, even more preferably 5 to 400 mg / kg body weight / day, even more preferably 10 to 300 mg / kg body weight / day, even more preferably 15 to 200 mg / kg body weight / day, or most preferably 20 to 150 mg / kg body weight / day. Of course, the above administration method is one example, and other administration methods may be used. It is desirable that the administration method, dosage, administration period, administration interval, etc. of the anti-obesity agent to humans are determined by a controlled clinical trial.
[0030] The anti-obesity agent of the present invention can be administered to humans, but may also be administered to animals other than humans, including pets such as dogs, cats, rabbits, hamsters, guinea pigs, and squirrels; livestock such as cows and pigs; laboratory animals such as mice and rats; and animals kept in zoos, etc.
[0031] The anti-obesity agent of the present invention may be a pharmaceutical composition for preventing or treating obesity. The pharmaceutical composition includes drugs and quasi-drugs.
[0032] 《Effect》 The ground or extracted basil or coriander contained in the anti-obesity agent of the present invention contains an active ingredient that exhibits anti-obesity effects. It is presumed that this active ingredient that exhibits anti-obesity effects can suppress fatty liver by reducing liver weight. It is also considered that obesity (obesity) can be prevented or treated by promoting the production of lipolytic enzymes and / or suppressing the production of lipolytic enzymes.
[0033] [2] Food composition for preventing or treating obesity The food composition for preventing or treating obesity of the present invention comprises the anti-obesity agent and a food or drink.
[0034] The food and drink products include food and beverages. Specific examples of the food include fresh food products such as salads; cooked food products such as steaks, pizzas, and hamburgers; fried food products such as stir-fried vegetables; vegetables such as tomatoes, green peppers, celery, bitter melon, carrots, potatoes, and asparagus, and cooked products made from these vegetables; confectioneries such as cookies, bread, biscuits, dry bread, cakes, rice crackers, yokan, puddings, jellies, ice creams, chewing gums, crackers, chips, chocolates, and candies; noodles such as udon, pasta, and soba; fish paste products such as kamaboko, ham, and fish sausages; dairy products such as cheese, cream, and butter; seasonings such as miso, soy sauce, dressing, ketchup, mayonnaise, soup base, noodle soup, curry powder, mirin, and roux; soybean foods such as tofu; agricultural and marine products such as furikake, tsukudani, and cereals; and konjac.
[0035] Examples of beverages include coffee beverages; cocoa beverages; vegetable juices obtained from the above-mentioned vegetables; fruit juice beverages such as grapefruit juice, orange juice, grape juice, and lemon juice; tea beverages such as green tea, black tea, sencha, and oolong tea; alcoholic beverages such as beer, wine (red wine, white wine, sparkling wine, etc.), sake, plum wine, sparkling wine, whiskey, brandy, shochu, rum, gin, and liqueurs; dairy beverages; soy milk beverages; liquid diets; and sports drinks.
[0036] The food or beverage includes feed and beverage for animals, such as primates including humans, cows, pigs, sheep, goats, horses, dogs, cats, rabbits, rats, and mice.
[0037] If desired, these foods or beverages may contain food additives and food ingredients, such as antioxidants, flavorings, acidulants, colorings, emulsifiers, preservatives, seasonings, sweeteners, spices, pH adjusters, stabilizers, vegetable oils, animal oils, sugars and sugar alcohols, vitamins, organic acids, fruit juice extracts, vegetable extracts, grains, beans, vegetables, meats, seafood, etc., either alone or in combination of two or more. The amounts of these food ingredients and food additives to be added may be appropriately determined within the range that does not impair the object of the present invention.
[0038] These foods or beverages can be subjected to common sterilization treatments, such as heat pressure sterilization using retort and autoclave, batch sterilization, plate sterilization, electric heating sterilization, microwave heating sterilization, and steam sterilization such as injection and infusion.
[0039] Foods and beverages include functional foods (beverages) and health foods (beverages). In this specification, "health foods (beverages)" refers to foods or beverages that have some effect on health or that can be expected to have an effect, and "functional foods (beverages)" refers to foods or beverages among the above-mentioned "health foods (beverages)" that are designed and processed to fully exhibit a bioregulatory function (i.e., the function of preventing obesity or obesity syndrome, or the function of alleviating or treating obesity or obesity syndrome). Functional foods and health foods can be in the form of granules, solids, liquids, capsules, gels, or tablets. EXAMPLES
[0040] The present invention will be specifically described below with reference to examples, but the scope of the present invention is not limited thereto.
[0041] Example 1 In this example, the anti-obesity effects of coriander and sweet basil were examined using KKAy mice, which develop severe diabetes due to obesity. Twenty-five 7-week-old male KKAy mice were divided into four groups and bred for four weeks: control group (group C), high-fat, high-sucrose diet group (group H), high-fat, high-sucrose diet + coriander (coriander) powder intake group (group HP), and high-fat, high-sucrose diet + basil powder addition group (group HB). Coriander (coriander) and basil leaves were freeze-dried and immediately powdered in a mixer, and added to the high-fat, high-sucrose diet at 1% (w / w). Cornstarch was substituted for the additives. After the breeding period, blood samples were taken, dissections were performed, and analysis was performed. In the HP group, as shown in Figure 1a, liver weight was significantly increased in the H group, which was fed a high-fat, high-sucrose diet, compared to the C group. On the other hand, liver weight was significantly decreased in the HP group, which was fed coriander (cilantro), compared to the H group. In addition, the expression level of CPT1α mRNA, one of the β-oxidation enzymes in the liver, was quantified by real-time PCR. CPT1α mRNA tended to be higher in the HP group compared to the H group (Figure 1b). Therefore, coriander (cilantro) is known to be effective in reducing fats and fat content It contains ingredients that activate the digestive system, and is thought to be effective in preventing obesity.
[0042] As shown in Figure 2a, liver weight was also significantly suppressed in the HB group. In addition, the expression level of SREPB1c mRNA, which is involved in TG synthesis, was quantified by real-time PCR. It tended to be lower in the HB group compared to the H group (Figure 2b). Therefore, basil contains components that reduce fat synthesis and is considered to be effective in suppressing obesity.
[0043] Example 2 In this example, the activation of CPT1α by coriander (coriander) extract was examined using cells. Ethanol extraction was carried out by adding 9 times the amount of ethanol to the freeze-dried coriander. After removing the solvent from the extract using an evaporator, it was dissolved in DMSO to prepare a sample for addition to cells. The extract was added to the medium of mouse liver cells Hepa-1 cells at 5 μg / mL or 25 μg / mL and cultured for 6 hours, then exchanged for serum-free medium and cultured for another 8 hours. The cells were harvested and CPT1α mRNA was quantified using real-time PCR. The expression level of CPT1α mRNA was significantly increased by adding 25 μg / mL of ethanol extract of coriander (coriander) compared to the control (Figure 3). Thus, coriander (coriander) has an important role in the regulation of liver fat. fat content It was believed to contain components that significantly promoted the solution.
[0044] Example 3 In this example, the effects of coriander (coriander) and basil extracts on mouse preadipocytes (3T3-L1 cells) were examined. Specifically, 3T3-L1 cells were co-cultured with mouse macrophage cells (RAW264.7 cells), and the effects of coriander (coriander) and basil extracts on the inflammatory state induced by the action of 3T3-L1 cells on RAW264.7 cells were examined. Cilantro and basil were freeze-dried, powdered, and extracted with 80% methanol. After extraction, the solvent was removed using an evaporator, and each was redissolved in DMSO to 5 mg / mL or 25 mg / mL. 3T3-L1 cells, which are mouse preadipocytes, were cultured in DMEM + 10% FBS medium. When the cells reached confluence, they were subcultured, and differentiation was induced for 10 days using drugs (1 μg / mL insulin, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.25 μM dexamethasone (DEX)). Then, cilantro or basil extracts (final concentrations 5 μg / mL, 25 μg / mL) were added and cultured for 24 hours. After 24 hours, RAW264.7 cells were added and co-cultured for 12 hours. After cell recovery, the expression levels of IL-6 or IL-1β genes were measured using real-time PCR. The results are shown in Figure 4.
[0045] Co-culturing 3T3-L1 cells and RAW264.7 cells significantly increased the mRNA levels of inflammatory cytokines IL-6 and IL-1β compared to the control, indicating that co-culturing induced inflammation in RAW264.7 cells. When 3T3-L1 cells were cultured with extracts of coriander or basil, IL-6 mRNA was significantly decreased at 25 μg / mL of coriander, and IL-1β mRNA expression was significantly decreased at 5 and 25 μg / mL of basil. These results indicate that coriander and basil extracts have an anti-inflammatory effect on adipocytes.
[0046] Example 4 It has been reported that adipocytes have 4-1BB, a member of the TNF receptor family, and that binding to 4-1BBL, a membrane-bound ligand of macrophages, induces inflammation. In this example, the effects of coriander extract and basil extract on the mRNA expression level of 4-1BB in mouse preadipocytes (3T3-L1 cells) were examined. The coriander extract and basil extract obtained in Example 3 were similarly added to the cells at a final concentration of 5 μg / mL or 25 μg / mL, and the cells were cultured for 24 hours. Then, RAW264.7 cells were cultured and co-cultured for 12 hours. After cell recovery, the expression level of the 4-1BB gene was measured using real-time PCR. The results are shown in FIG. 5. Basil extract significantly reduced the expression of 4-1BB mRNA. These results suggest that basil extract contains a substance that can suppress the transcription of 4-1BB, a member of the TNF receptor family. [Industrial Applicability]
[0047] The anti-obesity agent and food composition of the present invention can be used for the prevention or treatment of obesity or obesity syndrome.
Claims
1. A fat breakdown promoter comprising ground coriander or extract.
2. The lipolysis promoter according to claim 1 , wherein the ground material is a ground leaf material and the extract is a leaf extract.
3. The lipolysis promoter according to claim 1 or 2, wherein the extract is an alcohol extract.
4. A food composition for promoting lipolysis comprising the lipolysis promoter according to any one of claims 1 to 3 and a food or drink.
Citation Information
Patent Citations
A composition having anti-adipogenic and anti-obesity activity consisting of an extract of a cucurbitaceous plant or a purified extract isolated from an extract of a cucurbitaceous plant
JP2007513150A
Medicinal plant extract with anti-obesity efficacy
JP2009536223A
Composition for Prevention or Treatment of Obesity, Dyslipidemia, Fatty Liver or Insulin Resistance Syndrome Comprising Camphene as Active Ingredients
US20120035274A1
